NCT05905926

Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C

ENROLLING_BY_INVITATIONPHASE3INTERVENTIONAL

Trial Details

Start: 2023-02-17Est. Completion: 2031-07

Enrollment target: 150 participants

Locations

G & L Research, LLC, Foley, Alabama, United States
Advanced Research Center, Inc., Anaheim, California, United States
Prohealth Research Center, Doral, Florida, United States
I.H.S. Health, LLC, Kissimmee, Florida, United States
Valencia Medical and Research Center, Miami, Florida, United States
Orlando Health, Inc.- APH Center for Digestive Health and Nutrition, Orlando, Florida, United States
Florida Pharmaceutical Research and Associates, Inc., South Miami, Florida, United States
OSF Saint Francis Medical Center, Peoria, Illinois, United States
Riley Children's Health, Indianapolis, Indiana, United States
Maine Health, Portland, Maine, United States
Mankato Clinic/ Javara Research Ltd, Mankato, Minnesota, United States
Boys Town National Research Hospital, Boys Town, Nebraska, United States
SUNY Downstate Medical Center, Brooklyn, New York, United States
Advantage Clinical Trials, The Bronx, New York, United States
Atrium Health, Charlotte, North Carolina, United States
Duke University School of Medicine, Durham, North Carolina, United States
Wilmington Health, Wilmington, North Carolina, United States

Irritable Bowel Syndrome With Constipation (IBS-C)

This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapano…

Foley, United StatesEst. completion Sep 1, 2026

Irritable Bowel Syndrome With Constipation (IBS-C)

This is a randomized, double-blind, placebo-controlled dose-ranging study to assess the safety and efficacy of tenapanor…

Little Rock, United StatesEst. completion Jul 2026

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.